APS Support UK is dedicated to raising awareness of antiphospholipid syndrome (APS), supporting anyone affected by the condition and furthering research.
A qualitative study (n=10) of women with #APS following pregnancy/perinatal loss documented grief, self-blame and gaps in emotional support. Diagnosis sometimes helped explain previous losses, but bereavement care remains vital: https://t.co/KbCErA5lIY #BabyLoss
Cross-sectional study (38 PAPS, 26 APS/SLE; 35 controls): arthralgia affected 50% vs 80.8% (p=0.013). Most imaging markers of synovial inflammation did not differ significantly; joint effusion was higher in #APS/#SLE: https://t.co/n6RnHIpT1b #AntiphospholipidSyndrome
Glad to share this paper @MediPharma_MDPI
"Diagnosis and Management of Catastrophic #Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria"
https://t.co/0bMFL9dsyN
Case report: Bilateral vaso-occlusive #retinopathy revealed primary #APS in a 12-year-old girl. Following treatment, right-eye vision improved to 20/20; left-eye retinal detachment progressed. Early recognition matters: https://t.co/LmFl6J2Hvh
Meta-analysis (52 studies): aPL positivity in 19.1% of ischaemic stroke patients; higher odds of first stroke (OR 2.93), but no significant association with recurrence (OR 1.20). Single aPL positivity ≠ #APS diagnosis. https://t.co/HTJNUC3bUz
New review by Maria Laura Bertolaccini & Giovanni Sanna: aPS/PT antibodies may add diagnostic and prognostic value in #APS, with associations with thrombosis, obstetric morbidity, LA positivity and #seronegativeAPS : https://t.co/X4q5zvHdna
Acquired activated protein C resistance (APCr) and anti-protein C antibodies (anti-PC) antibodies are common in #antiphospholipid antibodies (aPL)-positive individuals, especially those with thrombotic antiphospholipid syndrome (APS), as demonstrated by a recent APS ACTION Registry study
𝗦𝘁𝘂𝗱𝘆 𝗣𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻
◦ 370 aPL-positive patients, categorized as: aPL-only (n=77), pregnancy morbidity (PM, n=43), venous #thromboembolism (VTE, n=132), arterial #thrombosis (AT, n=87), or combined VTE+AT (n=31), and 51 healthy controls.
◦ Prospective follow-up available for 283 patients (median 8.3 years).
𝗠𝗮𝗶𝗻 𝗥𝗲𝘀𝘂𝗹𝘁𝘀
◦ APCr markedly higher in all aPL-positive patient subgroups compared to healthy controls (p < 0.001). Greatest APCr observed in patients with VTE + AT and in triple aPL-positive patients.
◦ Anti-PC antibodies were resent in 42% of patients overall. High-avidity anti-PC significantly more prevalent in the VTE+AT group (79%) compared to aPL-only patients (38%, p < 0.05).
→ Strong association between APCr and high-avidity anti-PC.
◦ New thrombosis occurred in 25/283 (8.8%) patients during follow-up.
→ No significant association between APCr or anti-PC and new thrombotic events overall (p > 0.60).
◦ In the non-anticoagulated subgroup, patients with APCr showed a higher rate of thrombotic events (HR 4.5, 95% CI 0.8–25.9, p=0.14), but this did not reach statistical significance.
In this study APCr was highly prevalent across aPL-positive patients and is strongly linked to high-avidity anti-PC antibodies. However, no clear overall association with future thrombosis was found, likely due to confounding by widespread anticoagulation at baseline and relatively few events.
*Tohidi-Esfahani I, Venturelli V, Tektonidou M, et al. Prevalence and prognostic value of activated protein C resistance and anti-protein C antibodies in patients with antiphospholipid antibodies: an APS ACTION Registry study. Rheumatology (Oxford). Published online June 13, 2026.
🔗https://t.co/8lAdRRKfDv
Case series: 7 adults (67–90) with #IschaemicStroke and aPL positivity. Authors support targeted #APS testing in cryptogenic/recurrent/multifocal stroke, with persistent high-specificity confirmation before attribution; not routine screening: https://t.co/YYo9gYElgD
Systematic review of adrenal involvement in #APS/SLE-spectrum disease: 143 cases in the main analysis; 86.3% bilateral, 66.9% haemorrhage-dominant, and #AdrenalInsufficiency was the first manifestation in 73.6%: https://t.co/e3ARROxgWt
I'm glad to hear the LA County Board of Supervisors is supporting our bipartisan resolution to expand prenatal screening for antiphospholipid syndrome (APS) by declaring November 24th APS Awareness Day.
I'm proud to have partnered with @RepKatCammack on this bipartisan effort—it’s a matter of basic human decency and a call for smarter, more compassionate healthcare policy.
Let’s get this passed nationwide!
https://t.co/NbcuZWzlcQ
Dutch cohort: among 140 CTEPH/CTEPD patients with aPL results, 9 (6%) met #APS criteria; 67% had recurrent VTE and 44% were triple-positive. Consistent with guideline-recommended APS screening in CTEPH; numbers were small: https://t.co/7orRobdh2e #thrombosis
Singer Christina Perri addressed the LA County Board of Supervisors Tuesday about her battle to get prenatal testing for an easily treated blood-clotting condition known as Antiphospholipid Syndrome, or APS.
Video: LA County Board of Supervisors
#APS registry data matter. A Colombian registry-based cohort of 355 adults with thrombotic APS found recurrence risk was highest in the first 2 years; estimated recurrence was 31% at 5 years and 42% at 10. More registry data are vital: https://t.co/UndKVloRET #PatientRegistry